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Age-Based Characteristics of West Syndrome in 
Patients with Mitochondrial Disease
Purpose: West syndrome is a severe form of age-specific epilepsy that typically af-
fects infants younger than 2 years of age with mitochondrial disease. We aimed to 
examine age-specific characteristics of the syndrome in these patients.
Methods: We retrospectively analyzed 54 patients with West syndrome diagnosed 
with mitochondrial disease between March 2006 and March 2016. We compared 
treatment strategies and diagnostic and clinical variables between patients with 
early-onset (<6 months of age) and late-onset (≥6 months of age) seizures. 
Results: Seizure was the first symptom in 30 (90.9%) and 13 (65%) patients of the 
early-onset and late-onset groups, respectively (P=0.046). Delayed development 
was observed in 3 (9.1%) and 7 (35%) patients of the early-onset and late-onset 
groups, respectively (P=0.023). Lactate levels were normal in 17 patients (55%) of 
the early-onset group and 5 (25%) of the late-onset group (P=0.036), while initial 
brain magnetic resonance imaging (MRI) findings were normal in 23 (67.6%) and 8 
(40%) patients of the early-onset and late-onset groups, respectively. Final MRI fin-
dings were abnormal in 32 patients (94.1%) of the early-onset group and 18 (90%) 
of the late-onset group (P=0.036). Although ketogenic diets reduced seizure frequ-
ency in both groups, the difference was not significant.
Conclusion: There is no significant difference in epilepsy-related variables when 
patients are divided based on a cut-off age of 6 months. However, differences in the 
first symptom at onset and MRI findings were observed. Although lactate levels were 
not of significant diagnostic value in the early-onset group, they may be in the late-
onset group.
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Introduction
Mitochondrial disease is characterized by defects in mitochondrial energy me­
tabolism (e.g., insufficient production of adenosine triphosphate (ATP) via the re­
spiratory chain) as well as abnormal oxidative phosphorylation1,2). Mitochondrial 
disease is a clinically heterogeneous, multisystem disorder that represents a major 
cause of neurometabolic disorders during childhood3). Many patients with mito­
chondrial disease exhibit central nervous system (CNS) dysfunction, particularly 
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in the form of epilepsy4).
West syndrome is a severe form of encephalopathy/age­specific 
epilepsy that typically affects infants under 2 years of age. It is 
characterized by spasms, hypsarrhythmia on electroencephalo­
graphy (EEG), and delayed development. The incidence of West 
syndrome is 2 to 5 cases per 10,000 live births, with a prevalence 
rate of 1.5–2 per 10,000 children5­7). First­line treatment options 
include adrenocorticotropic hormone, high­dose prednisolone 
and vigabatrin; second­line options include the adoption of a 
ketogenic diet or the use of other antiepileptic drugs (AEDs)8­10). 
Patients with West syndrome diagnosed with mitochondrial dis­
ease show poor prognosis; 75–90% of these patients present with 
neurologic and developmental regression, and 50–60% present 
with recurrent seizures. 
While several studies have investigated mitochondrial disease 
and West syndrome individually, few studies have examined these 
two together in children1,2,11). Previous studies have revealed that 
the proportion of patients with West syndrome is high among 
patients with mitochondrial disease who experience seizures, and 
that prognosis is poor in this population11). In the present study, 
we aimed to examine age­specific characteristics of West synd­
rome in patients with mitochondrial disease. We also reviewed 
clinical/diagnostic features and treatment options based on age. 
Materials and Methods
1. Patients and inclusion criteria 
We conducted a retrospective analysis of 54 patients with West 
syndrome diagnosed with mitochondrial disease at the Depart­
ment of Pediatrics of Gangnam Severance Hospital between March 
2006 and March 2016. Among 372 patients who met the modified 
criteria for mitochondrial disease proposed by Bernier et al.12), 
248 patients with diagnoses of epilepsy were selected. A total of 
54 selected patients were diagnosed with West syndrome based 
on the following three features, in accordance with criteria out­
lined by the International League Against Epilepsy (ILAE): epi­
leptic spasms, developmental delay, and characteristic EEG pat­
terns (i.e., hypsarrhythmia)13). We then compared diagnostic and 
clinical variables between patients with early­onset (<6 months 
of age) and late­onset (≥6 months of age) seizures. Leigh synd­
rome (LS) that fulfilled the following criteria were included: 1) 
characteristic features of LS on neuroimaging, i.e., symmetrical 
hyperintense lesions in the basal ganglia and/or brainstem on 
T2­weighted magnetic resonance imaging; 2) abnormal energy 
metabolism indicated by a severe defect in oxidative phosphory­
lation or pyruvate dehydrogenase complex activity, and 3) genetic 
analysis of whole mtDNA performed at a diagnostic workup14). 
The study was approved by the Institutional Review Board of the 
Yonsei University Gangnam Severance Hospital (4­2011­0463).
2. Data collection for mitochondrial disease
Diagnostic evaluations for mitochondrial disease were per­
formed based on detailed clinical features, laboratory studies, 
imaging studies, histology studies, and enzymatic analyses. La­
boratory studies included serum lactic acid level. The degree of 
serum lactic acidosis was defined as mild, moderate, or severe if 
the increase relative to the normal reference values that is 0 to 
2.0 mmol/L was at least two­, three­, or more than three­fold, 
respectively. Imaging studies included brain magnetic resonance 
imaging (MRI) and magnetic resonance spectroscopy. Histo­
logical and enzymatic analyses were performed using muscle 
biopsy specimens obtained from the quadriceps femoris muscle. 
His tological findings associated with mitochondrial disease were 
categorized as either specific (e.g., the presence of ragged red 
fibers or succinate dehydrogenase (SDH) staining) or non­specific 
(e.g., percentages of muscle fiber types and sizes on light micro­
scopy). Biochemical enzyme analysis was performed to evaluate 
mitochondrial respiratory chain enzyme activity, which was re­
garded as defective when residual enzyme activity was less than 
10% of the reference value. In the present study, the clinical status 
of mitochondrial disease was classified according to severity, as 
follows: 0, mild (i.e., the patient is independently ambulatory, but 
may or may not be dependent on others during daily activities); 
1, moderate (i.e., the patient is confined to a wheelchair full­time 
or partially dependent on others during daily activities, with li­
mited communication abilities); 2, severe (i.e., the patient is bed­
ridden and totally dependent on others during daily activities; 3, 
expired. 
3. Data collection regarding epileptic features of West syndrome
We investigated features of West syndrome, including seizure 
type, EEG pattern, and treatment strategies. Seizure type was 
classified based on the first symptom (head drop, spasms, gene­
ralized seizures), in accordance with ILAE criteria13). EEG studies 
were graded based on the presence of generalized slowing or 
focal slowing of background rhythms, focal sharp waves, multi­
focal sharp waves, generalized epileptiform discharge, and classic/ 
modified hypsarrhythmic background activity. Treatment stra­
tegies included antiepileptic drugs, ketogenic diets, and surgery. 
Patients were evaluated for resistance to antiepileptic drugs based 
on the number of drugs utilized15). Ketogenic diets were assessed 
based on the frequency of seizures 6 months after initiation of 
the diet. 
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2. Statistical analysis
To assess the impact of age at the onset of the first seizure, pa­
tients were divided into early­onset (<6 months of age) and late­
onset ( ≥ 6 months of age) groups. We then compared variables 
associated with mitochondrial disease and West syndrome bet­
ween the two groups. All data were coded and analyzed using 
SPSS Statistics 22.0 (SPSS Inc, Chicago, IL, USA). Data were ana­
lyzed using descriptive statistics, including the mean, standard 
deviation, median, and range. Bivariate analyses were performed 
using t­tests and chi­square tests to evaluate differences between 
the groups. The level of statistical significance was set at P<0.05.
 
Results
1. Patient characteristics 
A total of 54 pediatric patients with West syndrome were diag­
nosed with mitochondrial disease between January 2006 and 
January 2016, among whom 25 were male (46.3%) and 29 were 
female (53.7%) (Table 1). Prenatal asphyxia and hypoxic­ischemic 
encephalopathy (HIE) injuries at birth were noted in 14.8% and 
9.3% of patients, respectively. Family history of mitochondrial 
disease was absent in 96.0% of patients. Initial symptoms included 
seizures (81.1%) and delayed development (18.9%). Mean age at 
first seizure onset was 6.3±6.0 months (range: 1 to 17 months). 
Most patients (92.6%) exhibited CNS involvement, although va­
rious organ involvement was also noted. Functional state at the 
Table 1. Clinical Characteristics of the 54 Included Patients
Characteristics Prevalence (n=54)
Subgroup based on age at first seizure
P-value
<6 months (n=34) ≥6 months (n=20)
Sex (male: female) 25 (46.3%):29 (53.7%) 17 (50%):17 (50%) 12 (60%):8 (40%) 0.477
Birth history
  Prematurity (<37 wks) 5 (9.3%) 3 (8.8%) 2 (10%) 0.619
  SGA (<2,500 g) 4 (7.4%) 3 (8.8%) 1 (5%) 0.525
  Prenatal asphyxia 8 (14.8%) 7 (20.6%) 1 (5%) 0.121
  HIE 5 (9.3%) 4 (11.8%) 1 (5%) 0.381
Family history
  None 52 (96.3%) 33 (97.1%) 19 (95%) 0.608
  Mitochondrial disease 0 (0%) 0 (0%) 0 (0%) -
  Seizure 2 (3.7%) 1 (2.9%) 1 (5%) 0.608
First presenting symptoms (n, %)
  Seizure 43/53 (79.6%) 30/33 (90.9%) 13/20 (65%) 0.046
  Delayed development 10/53 (18.5%) 3/33 (9.1%) 7/20 (35%) 0.023
Age at first symptoms (months) 5.1±4.2 (1–17) 2.7±1.4 (1–5) 9.3±4.2 (3–17) <0.001
Age at first seizure (months) 6.3±6.0 (1–29) 2.9±1.5 (1–5) 12.2±6.4 (6–29) <0.001
Organs involvement (n, %)
  Central nervous system 50 (92.6%) 32 (94.1%) 18 (90%) 0.475
  Gastrointestinal system 17 (31.5%) 12 (35.3%) 5 (25%) 0.318
  Respiratory system 9 (16.7%) 7 (20.6%) 2 (10%) 0.270
  Musculoskeletal system 6 (11.1%) 2 (5.9%) 4 (20%) 0.127
  Renal system 6 (11.1%) 5 (14.7%) 1 (5%) 0.268
  Cardiologic system 5 (9.3%) 4 (11.8%) 1 (5%) 0.381
  Eye 2 (3.7%) 1 (2.9%) 1 (5%) 0.608
  Endocrine system 2 (3.7%) 2 (5.9%) 0 (0%) 0.392
  Hematologic system 1 (1.9%) 0 (0%) 1 (5%) 0.370
Functional state
  Mild* 2 (3.7%) 2 (5.9%) 0 (0%) 0.392
  Moderate† 14 (25.9%) 8 (23.5%) 6 (30%) 0.600
  Severec‡ 33 (61.1%) 21 (61.8%) 12 (60%) 0.898
  Expired§ 5 (9.3%) 3 (8.8%) 2 (10%) 0.475
SGA, Small for gestational age; HIE, Hypoxic-ischemic encephalopathy.
*The patient is independently ambulatory, but may or may not be dependent on others during daily activities.
†The patient is confined to a wheelchair full-time or partially dependent on others during daily activities, with limited communication abilities.
‡The patient is bedridden and totally dependent on others during daily activitie.
§Expired.
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final follow­up visit was classified as mild, moderate, and severe 
in 3.7%, 25.9%, and 61.1% of patients, respectively. 
2. Diagnostic evaluations for mitochondrial disease 
The results of diagnostic evaluations for mitochondrial disease 
are presented in Table 2. Twenty­nine patients exhibited increases 
in serum lactic acid levels. Serum levels of lactic acid were normal, 
mildly increased, moderately increased, and severely increased 
in 22 (43.1%), 17 (33.3%), 9 (17.6%), and 3 (5.9%) patients, respec­
tively. Muscle biopsy findings and mitochondrial respiratory chain 
enzyme activity are also shown in Table 2. Mitochondrial respi­
ratory chain (MRC) complex I, II, and IV defects were noted in 
42 (89.4%), 1 (2.1%), and 4 (8.5%) patients, respectively. Specific 
findings for mitochondrial disease were noted 13 patients (24.5 
%) based on light microscopy analyses. Electron microscopy 
analyses revealed megaconia and pleioconia in 29 (55.8%) and 
26 (50.0%) patients, respectively. Initial MRI findings were normal 
in 31 patients (57.4%) and abnormal in 23 patients (42.6%). MRI 
findings at the last visit were normal in 5 patients (9.3%) and ab­
normal in 49 (90.7%). Abnormalities included abnormal signals 
in different areas of the brain or atrophy. Specifically, abnormal 
signals were observed in the basal ganglia in 6 patients (11.1%), 
in the thalamus in 8 patients (14.8%), and in the brainstem in 9 
patients (16.7%). Atrophy of the cerebellum and cortex was ob­
served in 28 patients (51.8%), while diffuse cerebral atrophy was 
observed in 47 patients (87.1%). 
3. Diagnosis and treatment of West syndrome 
In patients with West syndrome diagnosed with mitochondrial 
disease, seizure was the first symptom in 34 (63%) patients be­
fore the age of 6 months and in 20 (37.1%) patients after age of 6 
months. The latest age for seizure onset was 29 months (Table 
3). The first seizure type was spasm in 43 patients (79.6%), head 
drop in 4 patients (7.4%), and generalized seizure in 7 patients 
(13%). EEG revealed classic hypsarrhythmia in 37 patients (68.5 
%), generalized slowing of background rhythms in all patients, 
and focal slowing in 10 patients (18.9%). The epileptiform dis­
charge was multifocal in 49 patients (92.5%). Within the first 3 
months after diagnosis, the mean number of AEDs used was 1.7±
0.9, although this value increased to more than 2 AEDs after the 
age of 6 months, which indicates drug resistance. Patients whose 
seizures remained uncontrolled despite the use of more than 2 
AEDs were started on a ketogenic diet, which was effective in 
reducing seizures by 50% in 22 patients (71%). In addition, 20 pa­
tients (64.5%) experienced sustained reductions in the incidence 
of spasms for more than 6 months. Of the two patients who re­
ceived surgery, one underwent total callostomy, while the other 
underwent right frontal lobectomy with temporal disconnection.
4. Analysis of clinical characteristics by subgroup 
Clinical characteristics according to subgroup are presented in 
Table 1. The age at first symptom onset was 2.7±1.4 months in 
the early­onset group and 9.3±4.2 months in the late­onset group. 
Table 2. Results of Diagnostic Evaluations for Mitochondrial Disease
Evaluation Findings Prevalence (n=54)
Subgroup based on age at first seizure
P-value
<6 months (n=34) ≥6 months (n=20)
Serum lactic acidosis Normal 22/51 (43.1%) 17/31 (54.8%) 5/20 (25%) 0.036
Mildly increased (1- to 2-fold) 17/51 (33.3%) 7/31 (22.6%) 10/20 (50%) 0.043
Moderately increased (2- to 3-fold) 9/51 (17.6%) 5/31 (16.1%) 4/20 (20%) 0.723
Severely increased (≥3-fold) 3/51 (5.9%) 2/31 (6.5%) 1/20 (5%) 0.830
Syndromic Diagnosis Leigh syndrome 11/54 (20.4%) 7 (20.6%) 4 (20%) 0.623
Nonspecific mitochondrial disease 43/54 (79.6%) 27 (79.4%) 16 (80%) 0.623
Biochemical enzyme assay MRC complex I defect 42/47 (89.4%) 26/29 (89.7%) 16/18 (94.1%) 0.644
MRC complex II defect 1/47 (2.1%) 0/29 (0%) 1/18 (5.9%) 0.383
MRC complex IV defect 4/47 (8.5%) 3/29 (10.3%) 1/18 (5.9%) 0.502
Histopathologic assay under LM Normal 33/53 (62.3%) 18/34 (52.9%) 15/19 (78.9%) 0.061
Specific findings for mitochondrial diseases    13/53 (24.5%)                 10/34 (29.4%) 3/19 (15.8%) 0.223
Nonspecific abnormalities 7/53 (13.2%) 6/34 (17.6%) 1/19 (5.3%) 0.201
Histopathologic assay under EM Normal 23/52 (44.2%) 13/33 (39.4%) 10/19 (52.6%) 0.355
Megaconia 29/52 (55.8%) 20/33 (60.6%) 9/19 (47.4%) 0.773
Pleioconia 26/52 (50%) 17/33 (51.5%) 9/19 (47.4%) 0.355
MRI at initial diagnosis Normal 31/54 (57.4%) 23/34 (67.6%) 8/20 (40%) 0.047
Abnormal 23/54 (42.6%) 11/34 (32.4%) 12/20 (60%) 0.047
MRI at last visit Normal 5/54 (9.3%) 2/34 (5.9%) 2/20 (10%) 0.475
Abnormal 49/54 (90.7%) 32/34(94.1%) 18/20 (90%) 0.475
MRC, mitochondrial respiratory chain; LM, light microscopy; EM, electron microscopy; MRI, magnetic resonance imaging. 
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The age at first seizure was 2.9±1.5 months in the early­onset 
group and 12.2±6.4 months in the late­onset group. As classifi­
ca tion criteria were based on age, significant differences in these 
criteria were observed between the groups. There were 30 pa­
tients (90.9%) with earlier seizure onset who experienced seizure 
as the first symptom, relative to 13 patients (65%) with late­onset 
seizures (P=0.046). Delayed development was observed in 3 pa­
tients (9.1%) with early­onset seizures and 7 patients with late­
onset seizures (35%) (P=0.023). No significant differences in organ 
involvement, functional state, respiration, or feeding status were 
observed. The duration between the first diagnosis of West synd­
rome and the final follow­up was 8.0±5.1 years in the early­onset 
group and 9.8±5.1 years in the late­onset group.
5. Diagnostic analysis of mitochondrial disease by subgroup 
We evaluated serum levels of lactic acid based on the age at 
the onset of the first seizure (Table 2). Serum levels of lactic acid 
were normal in 17 patients (54.8%) of the early­onset group and 
5 patients (25%) of the late­onset group (P=0.036). Significant dif­
ferences in these abnormalities were observed only among pa­
tients with mild increases in serum lactic acid levels (early­onset 
group: 22.6% (n=7) vs. late­onset group: 50% (n=10) (P=0.043)). 
Initial MRI findings were normal in 23 patients (67.6%) of the 
early­onset group and 8 patients (40%) of the late­onset group 
(P=0.047). There was a statistically significant difference in the 
initial MRI findings between the two groups according to the age 
at onset. MRI findings at the last visit were abnormal in 32 patients 
(94.1%) of the early­onset group and 18 patients (90%) of the 
late­onset group, with no significant differences between the two 
groups (P=0.475). 
6. Diagnosis and treatment of West syndrome 
Because we classified first seizure onset based on age, signifi­
cant differences in this variable were observed between the two 
groups (P<0.001). No significant differences in seizure type or EEG 
findings (i.e., hypsarrhythmia, background rhythm, epileptiform 
Table 3. Diagnosis and Treatment of Infantile Spasms
Clinical Feature Specification Prevalence (n=54)
Subgroup based on age at first seizure
P-value
<6 months (n=34) ≥6 months (n=20)
First Seizure Type Head drop 4/54 (7.4%) 1/34 (2.9%) 3/20 (15%) 0.138
Spasm
  Flexor dominant 18/54 (33.3%) 12/34 (35.3%) 6/20 (30%) 0.690
  Extensor dominant 9/54 (16.7%) 5/34 (14.7%) 4/20 (20%) 0.441
  Indeterminant 16/54 (29.6%) 9/34 (26.5%) 7/20 (35%) 0.507
Generalized seizure
  GTC 4/54 (7.4%) 4/34 (11.8%) 0/20 (0%) 0.147
  GT 3/54 (5.6%) 3/34 (8.8%) 0/20 (0%) 0.241
EEG
  Background rhythm Generalized slowing 53/53 (100%) 34/34 (100%) 19/19 (100%) -
Focal slowing 10/53 (18.9%) 8/34 (23.5%) 2/19 (10.5%) 0.217
  Epileptiform Focal sharp/spike waves 4/53 (7.5%) 3/34 (8.8%) 1/19 (5.3%) 0.547
Multifocal sharp waves 49/53 (92.5%) 31/34 (91.2%) 18/19 (94.7%) 0.547
Generalized epileptiform discharge 36/53 (67.9%) 22/34 (64.7%) 14/19 (73.7%) 0.502
  Hypsarrhythmia Classic 37/53 (68.5%) 22/34 (64.7%) 15/20 (75%) 0.432
Atypical 17/53 (31.5%) 12/34 (35.3%) 5/20 (25%) 0.432
Treatment options
  Antiepileptic drugs 3 months after diagnosis 1.7±0.9 (1–4) 1.8±0.8 (1–3)                    1.7±1.1 (1–4) 0.916
6 months after diagnosis 2.6±0.9 (1–4) 2.7±0.9 (1–4) 2.4±0.9 (1–4) 0.282
1 year after diagnosis 2.6±1.0 (1–5) 2.6±1.0 (1–5)                   2.5±1.1 (1–4) 0.614
2 years after diagnosis 2.6±1.3 (0–6) 2.7±1.4 (0–6)                    2.6±1.1 (1–5) 0.942
  Ketogenic diet Seizure reduction rate 
  Reduction >50% 22/31 (71.0%) 13/18 (72.2%) 9/12 (69.2%) 0.583
  Reduction <50% 2/31 (6.5%) 0/18 (0%) 2/13 (15.4%) 0.168
  No effect 7/31 (22.6%) 5/18 (27.8%) 2/12 (16.7%) 0.358
Retention rate
  Retention >6 months 20/31 (64.5%) 13/18 (72.2%) 7/12 (53.8%) 0.334
  Retention <6 months 11/31 (35.5%) 5/18 (27.8%) 6/12 (46.2%) 0.263
Epilepsy surgery Yes 2/54 (3.7%) 1/34 (2.9%) 1/20 (5%) 0.400
GTC, generalized tonic clonic; GT, generalized tonic; EEG, electroencephalography.
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hibit a sensitivity between 34–62%, and a specificity between 
83–100%28,29). Previous studies have also indicated that increases 
in lactate levels are more significant in children than in adults30). 
In the present study, lactate levels were not of significant diagno­
stic value in the early­onset group. However, significant changes 
were observed in patients of the late­onset group, indicative of 
greater diagnostic value in this group. These findings suggest 
that, even though lactate levels are more sensitive in children than 
adults, these levels are less useful prior to the age of 6 months. 
MRI abnormalities are reported in approximately 70–80% of 
patients with West syndrome31,32). The duration of spasms tends 
to be shorter in patients with normal MRI findings than in those 
with abnormal MRI findings. Developmental outcomes are also 
better for patients with normal MRI findings and worse for pati­
ents with perinatal injuries33,34). In the present study, MRI findings 
were normal in 67.6% of patients with early­onset seizures but 
only 40% of patients with late­onset seizures. However, at the 
last visit, findings were normal in 5.9% and 10% of patients with 
early­ and late­onset seizures, respectively. These findings sug­
gest that the timing of the MRI evaluation is important, and that 
continued MRI evaluations are necessary as brain development 
progresses.
The ketogenic diet is accepted as a potent antiepileptic treat­
ment for intractable childhood epilepsy35,36). Eun et al. reported 
that ketogenic diets exhibit dramatic efficacy even among pati­
ents with intractable infantile spasms37). However, some studies 
have suggested that ketogenic diets can be lethal in patients with 
underlying metabolic diseases38). The ketogenic diet is also known 
to promote metabolic stress in patients with MRC complex de­
fects, and its use is typically avoided in such cases39,40). However, 
Kang et al. reported that patients with such defects can tolerate 
the ketogenic diet when supplementary mitochondrial cocktail 
therapy is administered41). In the present study, we observed that 
ketogenic diets were effective in treating patients with West synd­
rome and mitochondrial disease, although there was no statisti­
cally significant difference between the two age groups. Nonethe­
 less, clinicians should remain aware of the potential compli cations 
associated with their use in this patient population. 
The present study is limited in that prospective randomization 
was not used to select participants or set other research para­
meters, as mitochondrial disease is incredibly rare. Despite these 
limitations, our analyses provide valuable data regarding a homo­
genous group of patients with West syndrome and mitochondrial 
disease. Our study is also advantageous in that patients were 
compared and analyzed according to the age at symptom onset. 
Previous studies have revealed that the proportion of patients 
with West syndrome is high among patients with mitochondrial 
discharge) were observed between the groups. In addition, we 
observed no significant differences in surgery rates or the use of 
AEDs or ketogenic diets between the two groups (Table 3).
 
Discussion
In the present study, we examined the age­specific characteri­
stics of West syndrome in 54 pediatric patients who were diag­
nosed with mitochondrial disease. West syndrome is usually 
clas sified as either cryptogenic or symptomatic, although ap­
proximately 60–80% of cases are symptomatic16,17) . While some 
studies have indicated that spasm is typically the first major 
symptom, followed by developmental delay, others have indi­
cated the reverse18,19). These differences are considered to be 
due to differences in the criteria for categorizing symptoms, as 
well as differences among patient groups and observers. In the 
present study, most patients in the early­onset group experienced 
spasm as the first symptom, while most patients in the late­onset 
group experienced developmental delay as the first symptom. 
These findings suggest that West syndrome should be considered 
when patients with mitochondrial disease present with develop­
mental delay after the age of 6 months, and that patients prior to 
this age should be evaluated for spasms, since developmental 
assessments may be ambiguous.
West syndrome is an epilepsy syndrome characterized by early 
onset, usually presenting between the ages of 4 and 7 months20). 
Bednarek et al. studied West syndrome by dividing patients into 
groups of those younger or older than 1 year . While there were 
similar characteristics, such as developmental delay and hypsarr­
hythmia, the etiology and EEG findings were different in each 
group21,22). The late­onset group was characterized by less­pro­
minent slow waves, more­numerous multifocal spikes, and more­ 
marked interhemispheric synchronization on interictal EEG. The 
treatment responses to vigabatrin and steroids are lower in pati­
ents with late­onset23,24). Gul Mert et al. reported that neurode­
velopmental outcomes are worse in patients with early­onset in­
fantile spasms25). In the present study, patients were categorized 
based on the cut­off age of 6 months, which was the highest in­
cidence. Although we observed no significant differences in 
seizure type, EEG findings, or treatment based on age, further 
studies are required to determine whether our findings were due 
to variables associated with mitochondrial disease or to West 
syndrome.
Lactic acidosis is the most recognized laboratory abnormality 
in patients with mitochondrial disease26,27). In patients with pri­
mary mitochondrial disease, true elevations in lactate levels ex­
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disease who experience seizures. 
In conclusion, our findings indicated that there was no signifi­
cant difference in epilepsy­related variables when patients with 
West syndrome and mitochondrial disease were divided based 
on a cut­off age of 6 months. However, differences in the first 
symptom at onset and MRI findings were observed according to 
age at onset. In addition, MRI findings were more specific in the 
late­onset group. Although our findings indicate that lactate 
levels were not of significant diagnostic value in the early­onset 
group, they were of diagnostic value in the late­onset group. Our 
findings also indicated that ketogenic diets are effective in redu­
cing symptoms in patients with West syndrome and mitochond­
rial disease. Taken together, our results can be applied to the 
diagnosis and treatment of West syndrome based on the age at 
disease onset. Future large­scale studies are required to develop 
a clinical protocol for age­related diagnosis and treatment. 
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요약
목적: 미토콘드리아 질환은 산화적 인산화의 결함으로 인한 세포 
에너지의 부족으로 발생하는 이질적인 질환이다. 이 질환은 소아에서 
대사질환의 중요한 원인이며 임상증상으로는 경련이 대표적이다. 웨
스트 증후군은 영아기에 특징적으로 보이는 뇌전증 증후군이다. 우리
는 미토콘드리아 질환에서 웨스트 증후군 환자의 임상 양상을 비교
분석하였다. 
방법: 본 연구는 2006년부터 2016년까지의 의무기록을 통해 후향
적 연구를 진행하였다. 미토콘드리아 질환으로 진단 된 환자 중 웨스
트 증후군으로 확인 된 54명의 소아를 대상으로 하였다. 환자군을 경
련 발생 연령  6개월을 기준으로 조기 발병 그룹과 후기 발병 그룹으
로 나누었고 이들의 임상 양상을 비교분석하였다. 
결과: 첫 임상증상으로 경련을 보이는 경우가 조기 발병 그룹에서 
90.9%, 후기 발병 그룹에서는 65% 였으며(P=0.046) , 발달 지연은 조
기 발병 그룹에서는 9.1%, 후기 발병 그룹에서는 35% 였다(P=0.023). 
또한 조기 발병 그룹에서 젖산 혈증은 45%, 초기 MRI 이상 소견은 
67.6%, 마지막 MRI 이상 소견은 94.1%에서 나타났고 후기 발병 그룹
에서 젖산 혈증은 75%, 초기 MRI 이상 소견은 40%, 마지막 MRI 이
상 소견은 90%에서 나타났다. 케톤생성 식이요법은 미토콘드리아 질
환을 가진 웨스트 증후군 환자 31명에서 시행하였고 22명의 환자에
서 경련 횟수가 50% 이상 감소하는 효과가 있었다. 
결론: 미토콘드리아 질환에서 웨스트 증후군 환자들을 경련 발생 
연령을 기준으로 비교분석 했을 때 경련 관련 요인에 대해서는 큰 차
이를 보이지 않았다. 하지만 미토콘드리아 질환 관련 요인과 MRI에 대
해서는 일부 의미 있는 차이가 있었다. 또한 케톤생성 식이요법은 미
토콘드리아 질환을 가진 웨스트 증후군 환자에서도 효과가 있었다.
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